DiPS 1016SevA
HVRDi007-A
General
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Disease associated phenotypes | no phenotypes |
External Databases (Donor) |
|
BioSamples | SAMEA5176970 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | No |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Harvard University Area IRB |
Approval number | F12897 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Harvard University Area IRB |
Approval number | F12897 |
Do you have obligations to third parties in regard to the use of the cell line? | Yes |
Please describe: | see MTA |
Is there an MTA available for the cell line? | Yes |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Any skin fibroblast that is part of some dermis.
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Other medium:
Base medium: StemFlex or mTeSR
Main protein source: Serum concentration: % |
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|
|
|||
SSEA-3 |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
||||
Alkaline Phosphatase |
Yes |
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
AFP |
Yes |
FLK1 |
Yes |
Morphology
In vitro spontaneous differentiation
Marker | Expressed |
GATA4 |
Yes |
GATA2 |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
Pax6 |
Yes |
N-CAM |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46, XY, Normal Human Male
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.